Alisha Bouge is the project manager for CIRM’s Clinical Advisory Panels (CAPs)
On the cusp of the official kickoff to football season, CIRM has had its own kickoff to celebrate. The first Clinical Advisory Panel (CAP) meeting took place on August 18, 2015 in Irvine, CA with Caladrius Bioscience, Inc. And just as every NFL team starts the season hopeful of a Super Bowl win, all our CAPs start out with equally lofty goals. That’s because under CIRM 2.0, the role of the CAP is to work with the clinical stage project teams we fund to help accelerate the development of therapies for patients with unmet medical needs and to give these projects the greatest likelihood of success.
In the case of Caladrius, the work is focused on treating metastatic melanoma, an aggressive and deadly form of skin cancer. You can read more about this clinical trial here.
Obstacles and challenges are inevitable in the lifecycle of research. CIRM hopes to help its grantees navigate through these hurdles as quickly and positively as possible by providing recommendations from expert advisors in the field. The intention is for the CAP meeting process to be that navigating vessel throughout the lifetime of each clinical stage project.
The CAPs will include at least three members: one CIRM science officer, a patient representative, and an external scientific advisor. The CAP will meet with the project team approximately four times a year, with the first meeting taking place in-person. Consider the CAP as the grantee’s special team, doing all they can to get that two-point conversion at the end of an already successful outcome, giving the grantee and their team just a few more points in their pocket to reach the ultimate success.
As the lead Science Officer on this first CAP, CIRM’s Ingrid Caras stated: “This is our opportunity to be good stewards of the taxpayers’ money.”
The mission and the message of the CAP was well received by Caladrius. After the CAP meeting, Anna Crivici, VP of Operations & Program Management at Caladrius, had this to say about her experience:
I thought that the meeting was very productive. Everyone on the Caladrius team appreciates the collaborative approach CIRM is taking on the program, as amply demonstrated during our successful first meeting. The discussion on every agenda topic was helpful and insightful. The opportunity to better understand the patient perspective will be especially beneficial and increasingly important as the Phase 3 program progresses. We are confident that this and future CAP meetings will help us advance and refine our strategic planning and execution.
CIRM is looking forward to the 2015/2016 CAP season. And while there is no Super Bowl incentive at the end of our season, there is the hope that CIRM’s efforts, both financially and collaboratively, will contribute to successful treatments for so many out there in need. That’s something well worth cheering for.
One thought on “CIRM CAP Kickoff to New Clinical Trials”
Great article about great work. Go team!